Spotify billionaire’s body scan startup has come to America
Neko Health’s New York launch marks the company’s first physical presence in the United States after raising close to $1 billion in funding. The service combines blood analysis, skin imaging, and metabolic assessment in a single hour, expanding from an earlier 15‑biomarker panel to 55 markers. Co‑founders David Ek and Hjalmar Nilsonne position the scan as a preventive‑medicine tool, priced at $500 and billed as eligible for Health Savings Accounts, though it remains outside traditional insurance coverage. Investor Farooq Abbasi of Preface Ventures, who has already undergone two scans, lauds the offering as a scalable model for making preventive care “cheap and accessible,” and predicts a future where Neko clinics proliferate across the country.
The launch arrives amid a broader surge of AI‑driven health diagnostics that aim to shift care from reactive treatment to early detection. Companies such as Everlywell, Thorne, and One Medical have introduced at‑home testing kits or subscription‑based primary‑care models, but Neko’s in‑clinic, multimodal scan differentiates itself through high‑resolution computer‑vision analysis and a comprehensive biomarker panel. This approach taps into a U.S. market where preventive‑care utilization is low, partly due to cost concerns and fragmented insurance reimbursement. By targeting HSA‑eligible consumers, Neko sidesteps traditional payer structures while appealing to affluent, health‑conscious customers willing to pay out‑of‑pocket for early insights.
Looking ahead, Neko’s success hinges on navigating regulatory scrutiny, scaling its clinic network, and convincing insurers to recognize the scan’s clinical value. The $500 price point may limit adoption to higher‑income segments unless the company can demonstrate cost‑savings through early disease detection. Data privacy and the interpretability of AI‑generated results will also draw regulatory attention. Investors will watch for FDA clearance, partnerships with health systems, and any price adjustments that could broaden the addressable market.
Key Takeaways
Neko Health’s first U.S. clinic offers a $500, AI‑powered scan that evaluates 55 biomarkers in one hour.
The company has raised nearly $1 billion and already lists over 300,000 prospective customers.
By billing through Health Savings Accounts, Neko bypasses traditional insurance but may still face adoption limits due to out‑of‑pocket cost.
Future growth depends on regulatory approval, clinic expansion, and evidence that the scan reduces downstream medical expenses.
About the Source
This analysis is based on reporting by TechCrunch. Here is a short excerpt for context:
Farooq Abbasi, an investor in Neko Health, talked to Equity about the hot health tech company and what's next for it.Read the original at TechCrunch
